Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure.

Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Cauda R, De Luca A.

Infection. 2011 Dec;39(6):563-9. doi: 10.1007/s15010-011-0183-8.

PMID:
21866336
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C.

HIV Med. 2004 Sep;5(5):352-9.

4.

Clinical benefit of interventions driven by therapeutic drug monitoring.

Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V.

HIV Med. 2005 Sep;6(5):360-5.

5.

Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.

Lillemark MR, Gerstoft J, Obel N, Kronborg G, Pedersen C, Jørgensen LB, Madsen TV, Katzenstein TL.

J Med Virol. 2011 Mar;83(3):377-83. doi: 10.1002/jmv.21997.

PMID:
21264856
6.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA..

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
7.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study..

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
8.

Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V.

Pediatr Infect Dis J. 2009 Sep;28(9):826-30. doi: 10.1097/INF.0b013e3181a458f9.

PMID:
19654564
9.

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P.

AIDS. 2000 Jul 7;14(10):1333-9.

PMID:
10930147
10.

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.

Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC.

Indian J Med Microbiol. 2009 Jul-Sep;27(3):231-6. doi: 10.4103/0255-0857.53205.

11.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group..

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
12.

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A.

J Antimicrob Chemother. 2009 Jul;64(1):109-17. doi: 10.1093/jac/dkp132.

PMID:
19398461
13.

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group..

Antivir Ther. 2009;14(3):359-69.

PMID:
19474470
14.

Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team..

Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017.

15.

Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.

Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):68-74.

PMID:
16340476
17.

[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].

Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; ClinSurv-Studiengemeinschaft (gleichwertiger Beitrag)..

Dtsch Med Wochenschr. 2010 Jun;135(23):1166-70. doi: 10.1055/s-0030-1255124. German.

PMID:
20514595
19.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
20.

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.

Duong M, Buisson M, Peytavin G, Kohli E, Piroth L, Martha B, Grappin M, Chavanet P, Portier H.

Ann Pharmacother. 2005 Apr;39(4):603-9.

PMID:
15713788

Supplemental Content

Support Center